|Bid||44.30 x 1800|
|Ask||44.70 x 800|
|Day's Range||44.50 - 45.67|
|52 Week Range||35.30 - 45.69|
|Beta (3Y Monthly)||0.48|
|PE Ratio (TTM)||52.08|
|Forward Dividend & Yield||1.40 (3.08%)|
|1y Target Est||46.14|
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arrowhead ...
AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.
AstraZeneca plc (NYSE: AZN ) faced a clinical setback in a study evaluating a combo drug regimen in non-small cell lung cancer, or NSCLC. What Happened AstraZeneca said a Phase 3 study dubbed NEPTUNE that ...
A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday. The late-stage clinical trial was testing Imfinzi, chemically known as durvalumab, along with another treatment tremelimumab and compared the combination to platinum-based chemotherapy to treat patients whose cancer had spread beyond the lungs.
AstraZeneca has disclosed a setback for one of its key cancer treatments, saying a trial involving immunotherapy drug Imfinzi was no more effective than regular chemotherapy at treating advanced lung cancer. for early stage lung cancer, and the Anglo Swedish drugmaker has been rolling out trials combining it with different immunotherapy drugs to assess its effectiveness at treating later stages of the disease. The theory is that combining two immunotherapy drugs together into one treatment could boost survival rates.
BEIJING/SHANGHAI, Aug 20 (Reuters) - China on Tuesday added 148 drugs to its list of medicines covered by basic medical insurance schemes, part of a push to lower patients' out-of-pocket costs in one of the world's largest drug markets, state media reported. AstraZeneca's Kombiglyze and Merck & Co's Janumet diabetes treatments are among the drugs that will now be covered by national insurance, according to the updated list published by China's National Healthcare Security Administration. As it published the updated list of 2,643 drugs on its website on Tuesday, the healthcare administration said the adjustment was crucial to improving the efficient use of the country's medical insurance funds.
DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor in patients with and without type 2 diabetes
J Sainsbury on Tuesday continued its recovery from a 30-year low after data showed the supermarket chain was the best performer of the top four for the first time in nearly two years.
European shares fell on Tuesday after two sessions of robust gains as optimism over hopes of stimulus in major economies waned and investors awaited more guidance from central banks. Concerns about Italy's government further dented sentiment, though Italian bond yields fell after Prime Minister Giuseppe Conte said he would resign, potentially paving the way for a new coalition government. Markets in Italy have been volatile since the leader of the League, Matteo Salvini, pulled support from his coalition arrangement with the 5-Star Movement on August 8.
European shares rose for the third straight session on Tuesday, building on a recovery since late last week as British drugmaker AstraZeneca surged on results of a late-stage study. Shares of the drugmaker rose 1.5% after the company said its diabetes drug Farxiga met the main goal of the study for the treatment of patients with heart failure.
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
AstraZeneca and Merck’s LYNPARZA when added to standard-of-care bevacizumab significantly increased the time women lived without disease progression or death
Last week, AstraZeneca plc (NYSE: AZN) reported positive results for its prostrate cancer treatment Lynparza for patients with certain genetic profiles. Ahmad wrote in a note on Tuesday that AstraZeneca’s incremental success changes the game for Clovis.
As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.